425 related articles for article (PubMed ID: 29386072)
41. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
42. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.
Ding H; Chang J; Liu LG; Hu D; Zhang WH; Yan Y; Ma LY; Li ZC; Ma YJ; Hao SG; Tao R
Int J Hematol; 2015 Aug; 102(2):181-7. PubMed ID: 25997870
[TBL] [Abstract][Full Text] [Related]
43. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB
Lancet; 2016 Apr; 387(10027):1540-1550. PubMed ID: 26712084
[TBL] [Abstract][Full Text] [Related]
44. PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Kambhampati S; Mei MG; Godfrey J; Siddiqi T; Salhotra A; Chen R; Smith E; Popplewell LL; Herrera AF
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e893-e897. PubMed ID: 35778267
[TBL] [Abstract][Full Text] [Related]
45. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
Ott PA; Bang YJ; Berton-Rigaud D; Elez E; Pishvaian MJ; Rugo HS; Puzanov I; Mehnert JM; Aung KL; Lopez J; Carrigan M; Saraf S; Chen M; Soria JC
J Clin Oncol; 2017 Aug; 35(22):2535-2541. PubMed ID: 28489510
[TBL] [Abstract][Full Text] [Related]
46. PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
Zheng W; Gao Y; Ke X; Zhang W; Su L; Ren H; Lin N; Xie Y; Tu M; Liu W; Ping L; Ying Z; Zhang C; Deng L; Wang X; Song Y; Zhu J
BMC Cancer; 2018 Sep; 18(1):910. PubMed ID: 30241515
[TBL] [Abstract][Full Text] [Related]
47. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
[TBL] [Abstract][Full Text] [Related]
48. Setting dictates efficacy of pembrolizumab in TNBC.
Sidaway P
Nat Rev Clin Oncol; 2019 Feb; 16(2):66. PubMed ID: 30573793
[No Abstract] [Full Text] [Related]
49. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
Plimack ER; Bellmunt J; Gupta S; Berger R; Chow LQ; Juco J; Lunceford J; Saraf S; Perini RF; O'Donnell PH
Lancet Oncol; 2017 Feb; 18(2):212-220. PubMed ID: 28081914
[TBL] [Abstract][Full Text] [Related]
50. Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas.
Reiss SN; Yerram P; Modelevsky L; Grommes C
J Immunother Cancer; 2017 Dec; 5(1):99. PubMed ID: 29254497
[TBL] [Abstract][Full Text] [Related]
51. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
Ott PA; Elez E; Hiret S; Kim DW; Morosky A; Saraf S; Piperdi B; Mehnert JM
J Clin Oncol; 2017 Dec; 35(34):3823-3829. PubMed ID: 28813164
[TBL] [Abstract][Full Text] [Related]
52. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
Dada R
Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
[TBL] [Abstract][Full Text] [Related]
53. [Ring-shaped lesions on a lung scan].
Coşkuntürk M; Aarntzen EHJG; van der Velden WJFM
Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30719883
[TBL] [Abstract][Full Text] [Related]
54. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Zinzani PL; Ribrag V; Moskowitz CH; Michot JM; Kuruvilla J; Balakumaran A; Zhang Y; Chlosta S; Shipp MA; Armand P
Blood; 2017 Jul; 130(3):267-270. PubMed ID: 28490569
[TBL] [Abstract][Full Text] [Related]
55. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
56. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Maio M; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan P; Ibrahim N; Marreaud S; van Akkooi ACJ; Suciu S; Robert C
N Engl J Med; 2018 May; 378(19):1789-1801. PubMed ID: 29658430
[TBL] [Abstract][Full Text] [Related]
57. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
[TBL] [Abstract][Full Text] [Related]
58. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
59. Pembrolizumab Treatment and Pathologic Therapeutic Evaluation for Granulocyte Colony-stimulating Factor-producing Bladder Cancer: A Case Report and Literature Review.
Muramatsu-Maekawa Y; Taniguchi T; Ito H; Nakane K; Kato T; Tsuchiya T; Miyazaki T; Koie T; Mizutani K
J Immunother; 2020 May; 43(4):134-138. PubMed ID: 32080020
[TBL] [Abstract][Full Text] [Related]
60. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
Phillips T; Brunvand M; Chen AI; Essell J; Chiappella A; Diefenbach C; Cheng J; Ramies D; Hirata J; Morschhauser F; Flinn IW
Am J Hematol; 2022 Jan; 97(1):E24-E27. PubMed ID: 34731510
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]